The use of qualitative approach to detect and assess potential drug-drug interactions which may decrease the effectiveness of oral contraceptives – pilot study and literature review

Karolina Kilińska; Magdalena Cerbin-Koczorowska; Arleta Matschay; Michał Mierzwicki; Karolina Chmaj-Wierzchowska

doi:10.20883/medical.e73

Authors

Karolina Kilińska Department of Pharmaceutical Technology, Pharmacy Practice Division, Poznan University of Medical Sciences, Poland
Magdalena Cerbin-Koczorowska Department of Pharmaceutical Technology, Pharmacy Practice Division, Poznan University of Medical Sciences, Poland
Arleta Matschay Department of Pharmaceutical Technology, Pharmacy Practice Division, Poznan University of Medical Sciences, Poland
Michał Mierzwicki Department of Pharmaceutical Technology, Pharmacy Practice Division, Poznan University of Medical Sciences, Poland
Karolina Chmaj-Wierzchowska Department of Mother and Child Health, Poznan University of Medical Sciences, Poland

DOI:

https://doi.org/10.20883/medical.e73

Keywords:

qualitative approach, combined oral contraceptives, drug interactions, contraceptive failures

Abstract

Aim. The aim of the pilot study was to assess the effectiveness of the tool designed for detecting potential drug-drug interactions of combined oral contraceptives (COCs) with particular emphasis on those which can affect their contraceptive action. A proper study protocol design seems to be essential for further analysis of more data and for establishing correlations between observed interactions and demographic variables.
Material and methods. The cross-sectional descriptive, retrospective study was carried out on Polish females from March to May 2013. Gathered data, including products used concomitantly with contraceptive drugs, were derived electronically by patients and underwent thematic analysis.
Results. Out of 49 respondents who agreed to participate in the study and fit the inclusion criteria only 15 derived qualitative data about other medicinal products they used. However, some of them sent their monthly report more than once, which gave the total of 158 drugs listed in 25 forms gathered during the whole pilot study. Fifty-three potential drug interactions were found, including 13 (24.53%) which could have decreased the effectiveness of contraceptive drugs.
Conclusions. Continuation of the study in accordance with the study protocol will result in identification of common potential drug-related problems, which may enable development of an educational solution for gynecologists, pharmacists and patients increasing their awareness of the potential risk of contraceptive failures and unintended pregnancies.

Downloads

Download data is not yet available.

References

United Nations Department of Economic and Social Affairs Population Division. World contraceptive Patterns 2013. [Internet] 2014 [cited 2014 Feb 16]; Available from: http://www.un.org/en/development/desa/population/publications/pdf/family/worldContraceptivePatternsWallChart2013.pdf

Medart ML. Hormonal contraception and risk of breast cancer. Antykoncepcja – aktualności. 2005;5:7–11.

Polish Gynecological Society's recommendations regarding contraception. Ginekol Dypl. 2006:27–31.

Erkkola R. Recent advances in hormonal contraception. Curr Opin Obstet Gynecol. 2007;19:547–553.

Serfaty D, Wildemeersch D, Verougstraete A, Creatsas G. European Society of Contraception oral contraceptives survey update: birth control methods in "Europe of the 12". Int J Fertil Menopausal Stud. 1995;40(Suppl. 2):73–79.

Pearl R. Factors in Human Fertility and their statistical evaluation. Lancet. 1933;225:607–611.

Trussel J. Understanding contraceptive failure. Best Pract Res Clin Obstet Gynaecol. 2009;23(2):199–209.

Back DJ, Orme ML. Pharmacokinetic drug interactions with oral contraceptives. Clin Pharmacokinet. 1990;18(6):472–484.

Al-Busaidi ZQ. Qualitative research and its uses in health care. Sultan Qaboos Univ Med J. 2008;8(1):11–19.

Dickinson BD, Altman RD, Nielsen NH, Sterling ML. Drug interactions between oral contraceptives and antibiotics. Obstet Gynecol. 2001;98:853–860.

Fotherby K. Interactions with oral contraceptives. Am J Obstet Gynecol. 1990;163:2153–2159.

Archer JS, Archer DF. Oral contraceptive efficacy and antibiotic interaction: a myth debunked. J Am Acad Dermatol. 2002;46:917–923.

DRossi SS, Hersh EV. Antibiotics and oral contraceptives. Dent Clin North Am. 2002;46:653–664.

Dinger J, Minh TD, Buttmann N, Bardenheuer K. Effectiveness of Oral Contraceptive Pills in a Large US. Cohort Comparing Progestogenand Regimen. Obstet Gynecol. 2011;117:33–40.

World Health Organization. Medical Eligibility Criteria for Contraceptive Use (3rd edn) 2010. [Internet] 2013 [cited 2013 July 8]; Available from: http:// www.who.int/reproductivehealth/publications/family _planning/9789241563888/en/index.html.

Official Polish Gynecological Society Expert Panel position on reasons for hormonal contraceptive failure. Ginekol Pol. 2011;82:313–317.

Will-Shahab L, Bauer S, Kunter U, Roots I, Brattström A. St John’s wort extract (Ze 117) does not alter the pharmacokinetics of a low-dose oral contraceptive. Eur J Clin Pharmacol. 2009;65:287–294.

Schwarz UI, Büschel B, KirchWSchwarz UI, Büschel B, Kirch W. Unwanted pregnancy on self-medication with St John's wort despite hormonal contraception. Br J Clin Pharmacol. 2003;55:112–113.

Murphy PA. St. John's Wort and oral contraceptives: reasons for concern? J Midwifery Womens Health. 2002;47:447–450.

Hall SD, Wang Z, Huang SM, Hamman MA, Vasavada N, et al. The interaction between St John’s wort and an oral contraceptive. Clin Pharmacol Ther. 2003;74:525–535.

Murphy PA, Kern SE, Stanczyk FZ, Westhoff CL. Interaction of St. John’s wort with oral contraceptives: effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding. Contraception. 2005;71:402–408.

Yue QY, Bergquist C, Gerdén B. Safety of St John’s wort (Hypericum perforatum). Lancet. 2000;355:576–577.

Lewis SJ, Oakey RE, Heaton KW. Intestinal absorption of oestrogen: the effect of altering transit-time. Eur J Gastroenterol Hepatol. 1998;10:33–39.

Lewis SJ, Heaton KW, Oakey RE, MGarrigle HH. Lower serum oestrogen concentrations associated with faster intestinal transit. Br J Cancer. 1997;76(3):395–400.

Sher A, Rahman A. Role of diet on the enterohepatic recycling of estrogen in women taking contraceptive pills. J Pak Med Assoc. 1994;44:213–215.

González A, Fernández N, Sahagún A, García JJ, Diez MJ, Castro LJ, et al. Effect of glucomannan and the dosage form on ethinylestradiol oral absorption in rabbits. Contraception. 2004;70:423–427.

Fernández N, Diez MJ, Terán MT, García JJ, Calle AP, Sierra M. Influence of Two Commercial Fibers in the Pharmacokinetics of Ethinylestradiol in Rabbits. J Pharmacol Exp Ther. 1998;286:870–874.

Carbo Medicinalis VP, Polfa Rzeszów: Medycyna Praktyczna; 2009. [Internet] 2013 [cited 2013 July 1]; Available from: http://www.medonet.pl/leki,profil-leku,1591519,1,carbo-medicinalis-vp,index.html

FRHGuidance (January 2011) Drug Interactions with Hormonal Contraception. Faculty of Sexual and Reproductive Healthcare Clinical Effectiveness Unit. [Internet] 2013 [cited 2013 June 28]; Available from: www.fsrh.org/pdfs/CUguidancedruginteractionshormonal.pdf

Helms SE, Bredle DL, Zajic J, Jarjoura D, Brodell RT, Krishnarao I. Oral contraceptive failure rates and oral antibiotics. J Am Acad Dermatol. 1997;36:705–710.

London BM, Lookingbill DP. Frequency of pregnancy in acne patients taking oral antibiotics and oral contraceptives. Arch Dermatol. 1994;130:392–393.

Hughes BR, Cunliffe WJ. Interactions between the oral contraceptive pill and antibiotics. Br J Dermatol. 1990; 122:717–718.

Hopkins S. Clinical toleration and safety of azithromycin. Am J Med. 1991;Suppl 3A:4–5.

Back DJ, Tjia C, Martin C, Miller E, Salmon P. The interaction between clarithromycin and combined oral contraceptive steroids. J Pharm Med. 1991;2:81–87.

de Groot AC, Eshuis H, Stricker BH. [Inefficacy of oral contraception during use of minocycline]. Ned Tijdschr Geneeskd. 1990;134(25):1227–1229.

Pedretti E, Brunenghi GM, Morali GC. Interazione tra antibiotici e contraccettivi orali: la spiramicina. Quad Clin Ostet Ginecol. 1991;46:153–4.

Maggiolo F, Puricelli G, Dottorini M, Caprioli S, Bianchi W, Suter F. The effect of ciprofloxacin on oral contraceptive steroid treatment. Drugs Exp Clin Res. 1991;17:451–454.

Csemiczky G, Alvendal C, Landgren BM. Risk for ovulation in women taking a low-dose oral contraceptive (Microgynon) when receiving antibacterial treatment with a fluoroquinolone (ofloxacin). Adv Contracept. 1996;12:101–109.

Back DJ, Tjia J, Martin C, Millar E, Mant T, Morrison P, et al. The lack of interaction between temafloxacin and combined oral contraceptive steroids. Contraception. 1991;43:317–323.

Scholten PC, Droppert RM, Zwinkels MG, Moesker HL, Nauta JJ, Hoepelman IM. No interaction between ciprofloxacin and an oral contraceptive. Antimicrob Agents Chemother. 1998;42:3266–3268.

Ernst E. Second thoughts about safety of St. John's Wort. Lancet. 1999;354:2014–2015.

Pfrunder A, Schiesser M, Gerber S, Haschke M, Bitzer J, Drewe J. Interaction of St John’s wort with low-dose oral contraceptive therapy: a randomized controlled trial. Br J Clin Pharmacol. 2003;56:683–690.

Chief Medical Officer (CO). Fact Sheet for Health Care Professionals. Interactions between St John’s Wort (Hypericum perforatum) preparations. CM/CO/2000/4. London, UK: Department of Health; 2000 [cited 2013 July 3]; Available from: http://open.gov.uk-mca/mcahome.htm.

Harmonet – Summary of Product Characteristics, Pfizer Europe.

Jarosz M, Dzieniszewski J. Drug-food interctions – an important clinical problem. Służ Zdr. 2000:78–79